AR050626A1 - Composicion quimica y metodo para tratar desorden gastrointestinal - Google Patents

Composicion quimica y metodo para tratar desorden gastrointestinal

Info

Publication number
AR050626A1
AR050626A1 ARP050103687A ARP050103687A AR050626A1 AR 050626 A1 AR050626 A1 AR 050626A1 AR P050103687 A ARP050103687 A AR P050103687A AR P050103687 A ARP050103687 A AR P050103687A AR 050626 A1 AR050626 A1 AR 050626A1
Authority
AR
Argentina
Prior art keywords
chemical composition
gastrointestinal disorder
treat gastrointestinal
effective
subject
Prior art date
Application number
ARP050103687A
Other languages
English (en)
Spanish (es)
Inventor
Ryohei Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35229739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050626(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR050626A1 publication Critical patent/AR050626A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP050103687A 2004-09-02 2005-09-02 Composicion quimica y metodo para tratar desorden gastrointestinal AR050626A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60652104P 2004-09-02 2004-09-02
US66631705P 2005-03-30 2005-03-30
US66659305P 2005-03-31 2005-03-31

Publications (1)

Publication Number Publication Date
AR050626A1 true AR050626A1 (es) 2006-11-08

Family

ID=35229739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103687A AR050626A1 (es) 2004-09-02 2005-09-02 Composicion quimica y metodo para tratar desorden gastrointestinal

Country Status (16)

Country Link
US (2) US8748481B2 (https=)
EP (1) EP1791545B1 (https=)
JP (4) JP2008511541A (https=)
KR (4) KR20180033310A (https=)
CN (1) CN102885821A (https=)
AR (1) AR050626A1 (https=)
AU (1) AU2005278323B2 (https=)
BR (1) BRPI0514891A (https=)
CA (1) CA2577284A1 (https=)
ES (1) ES2603381T3 (https=)
IL (1) IL181332A (https=)
MX (1) MX2007002602A (https=)
NO (1) NO340989B1 (https=)
NZ (1) NZ553434A (https=)
TW (1) TWI387454B (https=)
WO (1) WO2006025599A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1562604T3 (da) * 2002-10-23 2012-04-02 Sucampo Ag Prostaglandinforbindelser til behandling af fedme
ATE489096T1 (de) * 2003-07-03 2010-12-15 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
EP1984027B1 (en) * 2006-01-24 2015-12-30 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
JP2015514681A (ja) * 2012-04-23 2015-05-21 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 下痢を伴う過敏性腸症候群の処置方法
MY176162A (en) * 2013-02-04 2020-07-24 Taisho Pharmaceutical Co Ltd Prophylactic or therapeutic drug for constipation
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
RU2695274C3 (ru) 1999-10-15 2020-11-09 Сукампо Аг Новые композиции и способы их стабилизации
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
WO2002094274A1 (en) 2001-05-18 2002-11-28 Sucampo Ag Cathartic composition
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
BRPI0317740B8 (pt) * 2002-12-27 2021-05-25 Sucampo Ag uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1
ATE489096T1 (de) 2003-07-03 2010-12-15 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner

Also Published As

Publication number Publication date
JP6408426B2 (ja) 2018-10-17
TWI387454B (zh) 2013-03-01
ES2603381T3 (es) 2017-02-27
EP1791545A1 (en) 2007-06-06
KR20170003712A (ko) 2017-01-09
KR20070048221A (ko) 2007-05-08
US20060063830A1 (en) 2006-03-23
EP1791545B1 (en) 2016-08-31
NO20071704L (no) 2007-05-31
US8748481B2 (en) 2014-06-10
NZ553434A (en) 2010-01-29
JP2018150354A (ja) 2018-09-27
WO2006025599A1 (en) 2006-03-09
KR20140019006A (ko) 2014-02-13
AU2005278323B2 (en) 2011-03-17
JP2015166377A (ja) 2015-09-24
BRPI0514891A (pt) 2008-06-24
JP2013049688A (ja) 2013-03-14
JP2008511541A (ja) 2008-04-17
US20140315994A1 (en) 2014-10-23
KR20180033310A (ko) 2018-04-02
IL181332A (en) 2015-09-24
MX2007002602A (es) 2007-04-25
CN102885821A (zh) 2013-01-23
TW200612901A (en) 2006-05-01
CA2577284A1 (en) 2006-03-09
AU2005278323A1 (en) 2006-03-09
NO340989B1 (no) 2017-07-31
IL181332A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
PY1972032A (es) Combinaciones para tratamientos de ehna/ehgna y enfermedades relacionadas
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
AR048645A1 (es) Tratamientos para el implante ocular de efecto terapeutico prolongado
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
UY28081A1 (es) Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celular
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
UY32032A (es) "2-[1-sustituido-1h-pirazolo[3,4-d]pirimidin-4-il](io, oxi o amino)-n-(heteroaril)alcanamidas"
CL2024002764A1 (es) Tratamiento de neurofibromas plexiformes asociados a neurofibromatosis tipo 1 (nf1) en pacientes pediátricos con mirdametinib
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
PH12021500006A1 (en) Methods of treatment and prevention of alzheimer's disease
MX2023005628A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
AR049844A1 (es) Memantina como tratamiento adyuvante con antipsicoticos atipicos en pacientes con esquizofrenia
ECSP055793A (es) Forma de administración de ibuprofeno sódico
MX2023012875A (es) Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.
AR050626A1 (es) Composicion quimica y metodo para tratar desorden gastrointestinal
AR124479A1 (es) Métodos de monitoreo de la digoxina con el uso de vibegrón para el tratamiento de la vejiga hiperactiva
CL2021001397A1 (es) Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
ES2491565T3 (es) Agente de transfección
AR107905A2 (es) Composición química y método para tratar desorden gastrointestinal
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
AR117861A1 (es) Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry
JOP20200046A1 (ar) طرق لعلاج أمراض مرتبطة بـtnf?

Legal Events

Date Code Title Description
FC Refusal